What to Expect When Starting Dulaglutide
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Introduction
Dulaglutide (Trulicity) is a GLP-1 receptor agonist given as a once-weekly subcutaneous injection for type 2 diabetes. It lowers blood sugar by stimulating insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite. It also provides cardiovascular benefits in patients with established heart disease. GI side effects are most prominent in the first weeks and typically improve with continued use.
Week-by-week timeline
First Injection and GI Adjustment
Administer the first injection on the same day each week. Common GI side effects in the first weeks include nausea, diarrhea, vomiting, and reduced appetite. These are dose-dependent and typically worst in the first 1-4 weeks. Start at the lower dose (0.75 mg/week) and escalate after 4 weeks if tolerated and additional glucose lowering is needed.
GI Effects Improving
Nausea and GI symptoms typically improve significantly by weeks 3-6 as the body adapts. Eating smaller, low-fat meals and avoiding fatty or spicy foods reduces GI symptoms. The appetite-suppressing effect persists and contributes to weight loss.
Dose Titration Assessment
After 4 weeks at 0.75 mg, your prescriber may increase to 1.5 mg/week if additional glycemic control is needed. This dose escalation may temporarily worsen GI symptoms for 1-2 weeks, then improve again.
Glycemic and Weight Response
Blood sugar levels (fasting and post-meal) should be measurably lower. Weight loss of 1-3 kg is typical over the first 3 months. For some patients, higher doses (3 mg or 4.5 mg/week) provide additional A1c lowering and weight loss.
Full Assessment
HbA1c checked at 3 months shows overall glycemic response. Cardiovascular benefits are established over years of therapy. Continue regular weekly injections — missing injections significantly reduces glycemic control. If you stop for more than a week, expect GI symptoms to recur when restarting.
When to call your doctor
Contact your healthcare provider if you experience:
- Persistent severe nausea or vomiting that prevents eating or drinking
- Signs of pancreatitis: severe persistent abdominal pain, especially radiating to the back (stop dulaglutide and seek care immediately)
- Rapid heart rate or palpitations
- Severe abdominal pain combined with vomiting
- Signs of allergic reaction: rash, difficulty breathing, facial swelling
- Symptoms of thyroid tumor (rare): neck lump, difficulty swallowing, hoarse voice (dulaglutide carries a black box warning for medullary thyroid carcinoma in rodents — avoid if personal or family history of MTC or MEN2)
- Signs of kidney problems: decreased urination, swelling, rapid weight gain (dehydration from GI side effects can affect kidneys)
Tips for getting started
Inject dulaglutide once weekly on the same day each week. The auto-injector pen can be used in the abdomen, thigh, or upper arm — rotate sites. Dulaglutide can be given without regard to meals. Refrigerate between 36-46°F; the pen can be kept at room temperature for up to 14 days. To reduce nausea: eat smaller, lower-fat meals; avoid spicy foods; eat slowly and avoid lying down immediately after eating. If vomiting persists beyond the first month, discuss with your provider.
Frequently asked questions
More about Dulaglutide
References
- [Regulatory] FDA Label: Trulicity (dulaglutide) Injection https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s020lbl.pdf Accessed 2026-03-01.
- [Regulatory] NIH MedlinePlus: Dulaglutide Injection https://medlineplus.gov/druginfo/meds/a614047.html Accessed 2026-03-01.
- [Clinical] REWIND Trial: Dulaglutide and Cardiovascular Outcomes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext Accessed 2026-03-01.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: